Price
No data yet.
Social Signal Score
Company Profile
- Sector
- Financial Services
- Industry
- Asset Management
- Beta
- 0.70
- Country
- US
Quote
Valuation & Ratios
Returns & Efficiency
Valuation
IBBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
108+54.76%Social Signal Score
Mentions (22)
- News (RSS)fool·7d ago·Neutral
Which Healthcare ETF Is the Better Buy: VanEck’s Pharma Fund PPH or iShares’ Biotech Fund IBB? One fund owns the big drugmakers that pay dividends. The other owns the broader biotech field, where stocks swing more. Here is which fits long-term investors.
View source ↗ - News (RSS)fool·7d ago·Positive
Which Healthcare ETF Is the Better Buy: State Street’s Pharma Fund XPH or iShares’ Biotech Fund IBB? XPH charges less and pays a higher yield, but IBB manages over 20 times the assets across a far broader set of research-driven biotech names.
View source ↗ - News (RSS)fool·8d ago·Positive
Two Ways to Play Biotech: FBT’s Return Edge vs. IBB’s Cost Advantage Fewer holdings, a higher fee, and a shallower drawdown set these two biotech funds apart in ways that could matter for long-term investors.
View source ↗ - Newszacks.com·20d ago·Positive
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now? Designed to provide broad exposure to the Health Care ETFs category of the market, the iShares Biotechnology ETF (IBB) is a smart beta exchange traded fund launched on 02/05/2001.
View source ↗ - News247wallst.com·22d ago·Neutral
$10,000 in Vanguard's Health Care ETF in 2004 Grew to $93,915, and It Still Charges 0.09% A single health care ETF launched two decades ago at rock-bottom cost has quietly compounded into a sum that surprises most investors, but whether its three closest rivals can match it depends entirely on what kind of risk you are
View source ↗ - Newszacks.com·24d ago·Neutral
Should You Invest in the iShares Biotechnology ETF (IBB)? Launched on February 5, 2001, the iShares Biotechnology ETF (IBB) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.
View source ↗ - News (RSS)fool·27d ago·Positive
Invesco’s RSPH or iShares’ IBB: Which Healthcare ETF Is the Better Long-Term Buy? RSPH offers broader healthcare exposure with lower volatility and higher dividend yield, while IBB provides concentrated biotech focus with stronger recent returns.
View source ↗ - Newscnbc.com·29d ago·Neutral
Biotech stocks are surging. How investors can play the new drug innovation boom Biotech stocks are rallying as clinical wins, M&A and new drug technologies revive the sector. Here are the ETFs and stocks analysts favor.
View source ↗ - 4chan /biz/biz·33d ago·Neutral
>IBB >LLY Medicine continuing to be the one industry benefitting the most from AI, without even investing in the infrastructure.
View source ↗ - News (RSS)fool·40d ago·Neutral
Better Buy: Fidelity Health Care ETF (FHLC) or iShares Biotechnology ETF (IBB)? FHLC offers broader sector exposure at a 0.08% expense ratio, compared with IBB's concentrated biotech focus at 0.44%, but IBB delivered stronger 1-year returns despite higher volatility.
View source ↗ - Newsetftrends.com·40d ago·Neutral
From Laggard to Leader: The Surprising Comeback of Healthcare Healthcare stocks have finally stepped back into the spotlight. After spending much of the past several years in the shadow of technology and AI, the sector has quietly emerged as one of the year's more compelling comeback stories.
View source ↗ - News (RSS)fool·41d ago·Neutral
Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH? IBB has delivered stronger returns than IYH but with dramatically sharper swings in both directions. Here is how to decide which trade-off fits your portfolio.
View source ↗ - Newsfool.com·42d ago·Positive
Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH? The iShares U.S. Healthcare ETF offers a lower expense ratio and a higher dividend yield than the iShares Biotechnology ETF. The iShares Biotechnology ETF provides concentrated exposure to over 200 biotech companies, while the iShares U.S. Healthcare ETF holds 100 diverse healthcare positions.
View source ↗ - News (RSS)fool·48d ago·Neutral
Better Healthcare ETF: Vanguard's Broad VHT vs. the iShares Biotechnology-Focused IBB VHT offers broad sector exposure, while IBB concentrates on biotech with higher growth but steeper drawdowns.
View source ↗ - News247wallst.com·53d ago·Negative
Big Pharma Got Its Tariff Exemption. The Biotech ETF Barely Blinked A 100% tariff on imported drugs just expanded to cover every drugmaker in the country, yet the biotech market's most closely watched fund treated it like a non-event. The reason says everything about who actually pays.
View source ↗ - News (RSS)fool·58d ago·Positive
Better Healthcare ETF: iShares Biotechnology-Focused IBB vs. Simplify's Broad PINK iShares offers lower fees and concentrated biotech exposure with stronger 1-year returns, while Simplify provides broader healthcare diversification and a higher dividend yield.
View source ↗ - Newsfool.com·58d ago·Neutral
Better Healthcare ETF: iShares Biotechnology-Focused IBB vs. Simplify's Broad PINK The iShares Biotechnology ETF carries a lower expense ratio and significantly larger assets under management (AUM) than the Simplify Health Care ETF. The Simplify Health Care ETF provides broader exposure across healthcare sub-sectors and a higher dividend yield than the biotechnology-focused iShares fund.
View source ↗ - Newsdefenseworld.net·58d ago·Negative
104,009 iShares Biotechnology ETF $IBB Shares Sold by Envestnet Asset Management Inc. Envestnet Asset Management Inc. decreased its stake in iShares Biotechnology ETF (NASDAQ: IBB) by 8.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,122,659 shares of the financial services provider's stock after selling 104,009 shares during
View source ↗ - News (RSS)fool·59d ago·Neutral
XLV vs IBB: How Healthcare Diversification Compares to Biotech Concentration XLV offers exposure to the broader healthcare sector, while IBB targets biotech innovators. Here's how the two stack up on risk, returns, and diversification.
View source ↗ - News247wallst.com·76d ago·Neutral
IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party? Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the trade still have teeth, or did the easy
View source ↗ - Newszacks.com·83d ago·Positive
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now? Designed to provide broad exposure to the Health Care ETFs category of the market, the iShares Biotechnology ETF (IBB) is a smart beta exchange traded fund launched on 02/05/2001.
View source ↗ - Newsbenzinga.com·94d ago·Neutral
Biotech Is Booming, But These 2 Stocks Missed the Memo Biotech stocks are having one of their best stretches in years. The iShares Biotechnology ETF (NASDAQ:IBB) jumped nearly 5% Wednesday and pushed to new all-time highs, according to data from Benzinga Pro.
View source ↗
Congress trades
- David Joycehouse · OH14 · disclosed May 8, 2019 (804d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
